{"id":"tecemotide-l-blp25","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL3039544","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tecemotide (L-BLP25) is a peptide vaccine consisting of a 25-amino acid peptide derived from the MUC1 tumor-associated antigen conjugated to a lipopeptide adjuvant. It is designed to activate both CD4+ and CD8+ T-cell responses against MUC1-expressing tumor cells. The vaccine approach aims to generate durable anti-tumor immunity in patients with advanced cancer.","oneSentence":"Tecemotide is a cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing MUC1 antigen.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:37:43.268Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (NSCLC), stage IIIB/IV"},{"name":"Advanced or metastatic non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT00828009","phase":"PHASE2","title":"BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2011-01-17","conditions":"Lung Cancer","enrollment":70},{"nctId":"NCT01496131","phase":"PHASE2","title":"Tecemotide (L-BLP25) in Prostate Cancer","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2011-10-24","conditions":"Prostate Cancer","enrollment":28},{"nctId":"NCT01462513","phase":"PHASE2","title":"L-BLP25 in Patients With Colorectal Carcinoma After Curative Resection of Hepatic Metastases","status":"COMPLETED","sponsor":"Prof. Dr. Carl Schimanski","startDate":"2011-08","conditions":"Colon Carcinoma, Rectum Carcinoma","enrollment":122},{"nctId":"NCT02049151","phase":"PHASE3","title":"Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"EMD Serono","startDate":"2014-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":35},{"nctId":"NCT01731587","phase":"PHASE1","title":"Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2001-01","conditions":"Non-small Cell Lung Cancer (NSCLC) Stage III","enrollment":""},{"nctId":"NCT01507103","phase":"PHASE2","title":"Tecemotide (L-BLP25) in Rectal Cancer","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2012-02","conditions":"Rectal Cancer","enrollment":124},{"nctId":"NCT01015443","phase":"PHASE3","title":"Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2009-12","conditions":"Non-Small Cell Lung Cancer","enrollment":285},{"nctId":"NCT01423760","phase":"NA","title":"Common Safety Follow-up Trial of Tecemotide (L-BLP25)","status":"TERMINATED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2012-01","conditions":"Non-Small Cell Lung Cancer, Multiple Myeloma","enrollment":27},{"nctId":"NCT01094548","phase":"PHASE2","title":"Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-01","conditions":"Multiple Myeloma","enrollment":34},{"nctId":"NCT00409188","phase":"PHASE3","title":"Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2007-01","conditions":"Non-small Cell Lung Cancer","enrollment":1513},{"nctId":"NCT00157209","phase":"PHASE2","title":"Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2000-08","conditions":"Lung Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":171},{"nctId":"NCT00960115","phase":"PHASE1, PHASE2","title":"Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-12","conditions":"Non-small Cell Lung Cancer","enrollment":178},{"nctId":"NCT00157196","phase":"PHASE2","title":"Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2005-04","conditions":"Carcinoma, Non-Small-Cell Lung, Lung Neoplasms","enrollment":22},{"nctId":"NCT00925548","phase":"PHASE3","title":"STRIDE - STimulating Immune Response In aDvanced brEast Cancer","status":"TERMINATED","sponsor":"EMD Serono","startDate":"2009-09","conditions":"Breast Cancer","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Stimuvax","EMD531444","L-BLP25","BLP25 Liposome Vaccine","BLP25 liposome vaccine"],"phase":"phase_3","status":"active","brandName":"Tecemotide (L-BLP25)","genericName":"Tecemotide (L-BLP25)","companyName":"Merck KGaA, Darmstadt, Germany","companyId":"merck-kgaa-darmstadt-germany","modality":"Biologic","firstApprovalDate":"","aiSummary":"Tecemotide is a cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing MUC1 antigen. Used for Non-small cell lung cancer (NSCLC), stage IIIB/IV, Advanced or metastatic non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}